LATEST
Maximus Federal Services agreed to acquire Agile DefensenewMount Logan Management agreed to acquire Alternative Fund AdvisorsnewDime Commercial Bancshares / ES BancsharesnewSalesforce agreed to acquire BrazeJV Investors / Oro Mobility HoldingsMorgan Stanley Capital Partners acquired The Rapid GroupCBRE Group agreed to acquire Onnec GroupBevPoint Capital agreed to acquire ESGMarwynn Holdings acquired Zhituo SoftwareAspire-Lakewood Holding acquired Dura Driver Control SystemsTransom Signal MergerSub / SoundThinkingSilgan / Trivium: minority stake
Open App
Agreement signedPublished 2 Nov 2023

HCR /
Cara Therapeutics, Inc.

Cara Therapeutics sells royalty interests to HCR

Buy side: HCR
Buy sideHCR
Target: Cara Therapeutics, Inc.
TargetCara Therapeutics, Inc.
Source · 2 Nov 2023
See the source
Buy side: HCR
Buy sideHCR
Target: Cara Therapeutics, Inc.
TargetCara Therapeutics, Inc.
01 / BuyerHCR
02 / TargetCara Therapeutics, Inc.
01

What happened

Cara Therapeutics, Inc. entered into a royalty interest purchase and sale agreement with HCR, exchanging certain royalty rights for up to $40 million in cash.

The agreement provides for an upfront payment of $17.5 million, with additional payments tied to a pricing approval and a sales milestone.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Cara Therapeutics sells royalty interests to HCR

This document is the source for the companies, stage, figure and people on this page.

Original filingUnlock with Pro
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request accessAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.